Beckman Coulter to Acquire Biosite Incorporated

Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical tests, and Biosite(R) Incorporated (Nasdaq: BSTE), a leading biomedical company commercializing proteomics discoveries for the advancement of medical diagnosis, have announced that they have entered into a definitive merger agreement under which Beckman Coulter will acquire all of Biosite's outstanding common stock in a cash tender offer of $85.00 per share, or approximately $1.55 billion on a fully diluted share basis.

The proposed transaction is expected to immediately accelerate Beckman Coulter's revenue growth, improve operating margins and be accretive to GAAP earnings in 2008 and beyond.


NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Beckman Coulter Inc. View Company Information

Posted on April 2, 2007








Get our eNewsletter
Over 6,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!

LATEST MICROBIOLOGY NEWS

MICROBIOLOGY EVENTS